A Disease Registry Encompassing the Care Of Patients With Multiple Myeloma on Panobinostat

Completed

• Conditions: Multiple Myeloma

• Registration Number: NCT04150289
• Lead Sponsor: pharmaand GmbH

Brief Summary

This study aims to describe current treatment patterns in the real-world setting among patients with multiple myeloma who are initiating treatment with (or changing treatment to) panobinostat and explore the associations with baseline patient characteristics, healthcare resource utilization, and clinical outcomes.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2019-10-31
• Study First Submitted QC: 2019-10-31
• Study Start: 2019-11-04
• Study First Posted: 2019-11-04
• Primary Completion: 2022-03-30
• Study Completion: 2022-03-30
• Status Verified: 2023-06
• Last Update Submitted: 2023-06-12
• Last Update Posted: 2023-06-15

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 248

Inclusion Criteria

• Willing and able to provide written informed consent
• At least 18 years of age
• Clinical diagnosis of multiple myeloma that meets published diagnostic criteria
• Initiating panobinostat within 60 days of enrollment
• ECOG performance status 0-1
• Availability of documentation from the patient's medical records regarding previous myeloma treatment, response, and duration of response
• Willing and able to complete the PRO questionnaire

Exclusion Criteria

• Diagnosed with any B-cell malignancy other than myeloma
• Estimated life expectancy <6 months
• Currently enrolled in any interventional clinical trial at study entry (note: patients who enroll in an interventional clinical trial after enrollment may remain in the registry)

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Response to treatment	24 months	Looking for patient reproted response to treatment with panobinostat

Trial Locations

Locations (7)

American Health Network Indiana; 🇺🇸 Indianapolis, Indiana, United States

Oncology Specialists of Charlotte; 🇺🇸 Charlotte, North Carolina, United States

Gettysburg Cancer Center; 🇺🇸 Gettysburg, Pennsylvania, United States

Southern Oncology Specialists; 🇺🇸 Huntersville, North Carolina, United States

Coastal Cancer Center; 🇺🇸 Myrtle Beach, South Carolina, United States

Southern Nevada Cancer Research Foundation and Optum Cancer Care; 🇺🇸 Las Vegas, Nevada, United States

Carolina Blood and Cancer Care Associates; 🇺🇸 Rock Hill, South Carolina, United States